Matinas BioPharma Investor Presentation Deck
15
MAT2203 Regulatory and Development Strategy
• Near-term development strategy refined to narrow initial target indication: treatment of invasive
aspergillosis in patients with limited treatment options (azole-intolerant, azole-resistant, or not
effectively managed with an azole)
Potential registration through leveraging LPAD pathway
Other regulatory designations protected and maintained (QIDP, ODD, Fast-Track, potential for Breakthrough Therapy)
●
●
-
Received written preliminary feedback from FDA on potential composite superiority endpoint and
overall study design in late December 2023
Feedback moves Company closer to alignment with FDA
Meeting to discuss and finalize protocol in process of being scheduled for early Q1
Preparations underway with global CRO in preparation for Phase 3 study implementation
Development and commercial partnership discussions remain ongoing
-
COPYRIGHT MATINAS BIOPHARMA 2024
MATINAS
BIOPHARMAView entire presentation